Inovio Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jacqueline Shea

Chief Executive Officer (CEO)

US$2.4m

Compensación total

Porcentaje del salario del CEO	30.8%
Permanencia del CEO	2yrs
Participación del CEO	0.08%
Permanencia media de la dirección	3.6yrs
Promedio de permanencia en la Junta Directiva	5.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jacqueline Shea en comparación con los beneficios de Inovio Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$2m	US$751k	-US$135m
Sep 30 2023	n/a	n/a	-US$165m
Jun 30 2023	n/a	n/a	-US$168m
Mar 31 2023	n/a	n/a	-US$241m
Dec 31 2022	US$4m	US$730k	-US$280m
Sep 30 2022	n/a	n/a	-US$332m
Jun 30 2022	n/a	n/a	-US$355m
Mar 31 2022	n/a	n/a	-US$328m
Dec 31 2021	US$2m	US$468k	-US$304m
Sep 30 2021	n/a	n/a	-US$221m
Jun 30 2021	n/a	n/a	-US$142m
Mar 31 2021	n/a	n/a	-US$188m
Dec 31 2020	US$2m	US$431k	-US$166m
Sep 30 2020	n/a	n/a	-US$180m
Jun 30 2020	n/a	n/a	-US$222m
Mar 31 2020	n/a	n/a	-US$123m
Dec 31 2019	US$1m	US$335k	-US$119m

Compensación vs. Mercado: La compensación total de Jacqueline($USD2.44M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD705.42K).

Compensación vs. Ingresos: La compensación de Jacqueline ha sido consistente con los resultados de la empresa en el último año.

CEO

Jacqueline Shea (57 yo)

2yrs

Permanencia

US$2,438,908

Compensación

Dr. Jacqueline E. Shea, Ph D., serves as Chief Executive Officer & President at Inovio Pharmaceuticals, Inc. since May 10, 2022 and serves as its Director since May 16, 2022. Dr. Shea served as Chief Opera...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jacqueline Shea	CEO, President & Director	2yrs	US$2.44m	0.079% $ 212.9k
Peter Kies	Chief Financial Officer	21.9yrs	US$1.16m	0.087% $ 233.8k
Laurent Humeau	Chief Scientific Officer	5.2yrs	US$1.14m	0.082% $ 220.7k
Thomas Hong	Manager of Investor Relations	no data	sin datos	sin datos
Robert Crotty	General Counsel & Chief Compliance Officer	2.5yrs	sin datos	sin datos
E. Brandreth	Senior Vice President of Quality Assurance	no data	sin datos	sin datos
Jeffrey Skolnik	Senior Vice President of Clinical Development	3.6yrs	sin datos	sin datos
Robert Juba	Senior Vice President of Biological Manufacturing & Clinical Supply Management	3.6yrs	sin datos	sin datos
Stephen Kemmerrer	Senior Vice President of Engineering Development	no data	sin datos	sin datos
Shawn Bridy	Senior Vice President of Business Development	3.3yrs	sin datos	sin datos
Mark Twyman	Chief Commercial Officer	3.6yrs	sin datos	sin datos
David Liebowitz	Senior Vice President of Early-Stage Clinical Development	less than a year	sin datos	sin datos

3.6yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de GBM se considera experimentado (3.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jacqueline Shea	CEO, President & Director	2yrs	US$2.44m	0.079% $ 212.9k
Wendy Yarno	Independent Director	6.4yrs	US$123.69k	0.024% $ 64.1k
Lota Zoth	Independent Director	5.3yrs	US$118.69k	0.017% $ 45.6k
Jay Shepard	Independent Director	4.3yrs	US$119.31k	0.019% $ 50.6k
Simon Benito	Independent Chairman of Board of Directors	20.4yrs	US$151.19k	0.030% $ 81.5k
David B. Weiner	Chairman of the Scientific Advisory Board & Director	24.3yrs	US$201.79k	0.31% $ 833.8k
Stanley Plotkin	Member of Scientific Advisory Board	14.9yrs	sin datos	sin datos
Ann Miller	Independent Director	5.2yrs	US$126.94k	0.021% $ 57.5k
Anthony Ford-Hutchinson	Member of Scientific Advisory Board	12.2yrs	sin datos	sin datos
Roger Dansey	Independent Director	3yrs	US$108.69k	0.014% $ 37.2k
Rafi Ahmed	Member of Scientific Advisory Board	5.5yrs	sin datos	sin datos

5.5yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de GBM se considera experimentada (5.4 años de antigüedad promedio).

Inovio Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

INOVIO Announces Board Changes

High number of new directors

INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

Inovio Pharmaceuticals, Inc. Announces Changes to Its Board

Recent updates

Inovio Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 13, 2024

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $35.937522 million.

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Full year 2023 earnings released: US$6.09 loss per share (vs US$14.07 loss in FY 2022)

Inovio Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 06, 2024

New minor risk - Profitability

Forecast to breakeven in 2026

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.15 loss in 3Q 2022)

Inovio Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Inovio Pharmaceuticals, Inc. Receives FDA Feedback That Data from Completed Phase 1/2 Trial of INO-3107

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.46 loss in 2Q 2022)

Inovio Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 2000 Value Index

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.36 loss in 1Q 2022)

INOVIO Presents New Data from A Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Inovio Reports Positive Phase 1B Results for INO-4201 as an Ebola Booster for rVSV-Zebov (Ervebo®)

Inovio Pharmaceuticals, Inc. Announces Strategic Reorganization and 11% Reduction of Full-Time Employees

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.29 loss in 3Q 2021)

INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800

Inovio Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Second quarter 2022 earnings released: US$0.46 loss per share (vs US$0.39 loss in 2Q 2021)

Inovio Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo(R) (cemiplimab) in Patients with Newly Diagnosed GBM

INOVIO Announces Board Changes

First quarter 2022 earnings released: US$0.36 loss per share (vs US$0.27 loss in 1Q 2021)

No longer forecast to breakeven

No longer forecast to breakeven

Inovio Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022

High number of new directors

INOVIO Updates on Phase 3 Program for VGX-3100 for HPV-Associated Cervical High-Grade Squamous Intraepithelial Lesions

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.12 profit in 3Q 2020)

INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico

Forecast to breakeven in 2023

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its Covid-19 DNA Vaccine Candidate, INO-4800

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.83 loss in 2Q 2020)

INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate

INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine against Middle East Respiratory Syndrome, a Coronavirus Disease

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 3000 Growth Index

Forecast breakeven pushed back to 2024

Inovio's Pan-Covid-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.26 loss in 1Q 2020)

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine

INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

INOVIO Announces Positive Results from REVEAL 1, Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-Based HPV Immunotherapy for the Treatment of High-Grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18

Full year 2020 earnings released: US$1.07 loss per share (vs US$1.21 loss in FY 2019)

Revenue beats expectations

QIAGEN N.V. and Inovio Pharmaceuticals Announces an Extension of Their Partnership with A New Master Collaboration Agreement to Develop Liquid Biopsy-Based Companion Diagnostic Cervical Dysplasia

INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa

Inovio Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 01, 2021

New 90-day high: €11.00

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150.45 million.

INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy in Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18

INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine

Inovio Pharmaceuticals, Inc. Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19

INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)

Inovio Presents Clinical Results of Its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (Cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme At Society for Neuro-Oncology 2020 Annual Meeting

Inovio Pharmaceuticals, Inc. Announces Initiation of Phase 2 Segment of Its Phase 2/3 Clinical Trial for Its Covid-19 Dna Vaccine Candidate

Third quarter 2020 earnings released: EPS US$0.12

Revenue misses expectations

Inovio Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Inovio Pharmaceuticals, Inc. Announces Changes to Its Board

INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2/3 Trial of COVID-19 Vaccine Candidate INO-4800

New 90-day low - €10.00

First half earnings released